AOD 9604

Product Description

AOD 9604 is a synthetic peptide fragment derived from the C-terminus of human growth hormone (hGH). It is classified as an experimental “lipolytic” (fat-oxidizing) peptide and has been investigated as a potential anti-obesity agent. It is not an approved drug, not a steroid, and not a natural supplement; it is widely sold as a research chemical and performance-enhancing product.

Chemical identity and structure

• Origin: AOD 9604 is a shortened, modified version of the carboxy-terminal (C-terminal) region of human growth hormone, specifically corresponding to amino acid residues 177–191 of the native hGH molecule.
• Description: It is a 15-amino acid peptide (approximately 1.8 kDa). The exact sequence is derived from the hGH fragment but includes a small structural modification (typically a terminal amino acid addition or substitution) intended to increase stability and preserve lipolytic activity while eliminating the growth-promoting and diabetogenic effects of full-length hGH.
• Formulation: AOD 9604 is supplied as a lyophilized (freeze-dried) white powder, typically reconstituted with bacteriostatic water or saline for subcutaneous or intramuscular injection.

Mechanism of action (purported)

AOD 9604 is designed to mimic the fat-burning properties of growth hormone without exerting its growth-promoting or blood sugar–raising effects. Research suggests it acts through the following pathways:

• Stimulation of lipolysis: AOD 9604 increases the activity of hormone-sensitive lipase in adipose tissue, promoting the breakdown of stored triglycerides into free fatty acids and glycerol.
• Inhibition of lipogenesis: It is reported to reduce the activity of enzymes involved in fat storage (e.g., fatty acid synthesis) and downregulate lipoprotein lipase, thereby decreasing fat accumulation.
• Mitochondrial metabolism: Some evidence suggests it may enhance the expression of genes involved in fat oxidation and mitochondrial biogenesis in fat cells, similar in intent to the effects of chronic caloric restriction.
• No IGF-1 secretion: Unlike intact hGH or growth hormone secretagogues, AOD 9604 does not stimulate hepatic IGF-1 release, and it does not significantly alter glucose or insulin levels at typical doses. This distinguishes it from many other growth-related peptides.

However, the exact molecular receptor and signaling cascades for AOD 9604 remain unclear. It is not a conventional androgen receptor ligand, and its specificity is still under scientific debate.

Clinical research and development history

AOD 9604 was originally developed by the Australian biotechnology company Metabolic Pharmaceuticals (later licensed by others). Its development path is instructive:

• Preclinical studies: In animal models of obesity, AOD 9604 reduced body weight and fat mass when administered as a daily injection.
• Phase II human trials (early 2000s): A randomized, placebo-controlled trial in obese patients reported that AOD 9604 was associated with a statistically significant reduction in abdominal fat (waist circumference) over a period of several weeks, without notable side effects or changes in glucose metabolism.
• Phase III trial (2005–2007): Larger and more definitive trials failed to reproduce the earlier results to a degree that met regulatory endpoints. The compound did not show sufficiently robust or consistent weight-loss benefits.
• Discontinuation: As a result of the failed Phase III study, further commercial development of AOD 9604 as a pharmaceutical anti-obesity drug was discontinued. It has never received approval from the FDA, EMA, TGA, or any other regulatory authority.

Since then, AOD 9604 has persisted on the “gray market” as a peptide sold for research purposes and unapproved use in bodybuilding and weight-loss circles.

Use in sports and bodybuilding (non-medical)

• AOD 9604 is commonly used by bodybuilders and fitness enthusiasts as a fat-loss aid during cutting phases. It is typically injected subcutaneously near adipose tissue deposits (e.g., abdomen or thighs) at doses of 300–1000 mcg per day, sometimes split into two doses.
• It is often stacked with other peptides (such as GHRP-2, GHRP-6, or IPA) or anabolic steroids, though such combinations are neither clinically validated nor safe.
• Proponents claim it preserves lean mass while reducing fat, but available human data do not demonstrate superiority over calorie restriction or exercise.

WADA and sport status

• AOD 9604 is prohibited at all times (in and out of competition) under the World Anti-Doping Agency (WADA) Prohibited List, specifically under S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics.
• It is specifically listed as a prohibited substance because it is a growth hormone fragment. Athletes testing positive face sanctions.

Chemical identity and structure

• Origin: AOD 9604 is a shortened, modified version of the carboxy-terminal (C-terminal) region of human growth hormone, specifically corresponding to amino acid residues 177–191 of the native hGH molecule.
• Description: It is a 15-amino acid peptide (approximately 1.8 kDa). The exact sequence is derived from the hGH fragment but includes a small structural modification (typically a terminal amino acid addition or substitution) intended to increase stability and preserve lipolytic activity while eliminating the growth-promoting and diabetogenic effects of full-length hGH.
• Formulation: AOD 9604 is supplied as a lyophilized (freeze-dried) white powder, typically reconstituted with bacteriostatic water or saline for subcutaneous or intramuscular injection.

Mechanism of action (purported)

AOD 9604 is designed to mimic the fat-burning properties of growth hormone without exerting its growth-promoting or blood sugar–raising effects. Research suggests it acts through the following pathways:

• Stimulation of lipolysis: AOD 9604 increases the activity of hormone-sensitive lipase in adipose tissue, promoting the breakdown of stored triglycerides into free fatty acids and glycerol.
• Inhibition of lipogenesis: It is reported to reduce the activity of enzymes involved in fat storage (e.g., fatty acid synthesis) and downregulate lipoprotein lipase, thereby decreasing fat accumulation.
• Mitochondrial metabolism: Some evidence suggests it may enhance the expression of genes involved in fat oxidation and mitochondrial biogenesis in fat cells, similar in intent to the effects of chronic caloric restriction.
• No IGF-1 secretion: Unlike intact hGH or growth hormone secretagogues, AOD 9604 does not stimulate hepatic IGF-1 release, and it does not significantly alter glucose or insulin levels at typical doses. This distinguishes it from many other growth-related peptides.

However, the exact molecular receptor and signaling cascades for AOD 9604 remain unclear. It is not a conventional androgen receptor ligand, and its specificity is still under scientific debate.

Clinical research and development history

AOD 9604 was originally developed by the Australian biotechnology company Metabolic Pharmaceuticals (later licensed by others). Its development path is instructive:

• Preclinical studies: In animal models of obesity, AOD 9604 reduced body weight and fat mass when administered as a daily injection.
• Phase II human trials (early 2000s): A randomized, placebo-controlled trial in obese patients reported that AOD 9604 was associated with a statistically significant reduction in abdominal fat (waist circumference) over a period of several weeks, without notable side effects or changes in glucose metabolism.
• Phase III trial (2005–2007): Larger and more definitive trials failed to reproduce the earlier results to a degree that met regulatory endpoints. The compound did not show sufficiently robust or consistent weight-loss benefits.
• Discontinuation: As a result of the failed Phase III study, further commercial development of AOD 9604 as a pharmaceutical anti-obesity drug was discontinued. It has never received approval from the FDA, EMA, TGA, or any other regulatory authority.

Since then, AOD 9604 has persisted on the “gray market” as a peptide sold for research purposes and unapproved use in bodybuilding and weight-loss circles.

Use in sports and bodybuilding (non-medical)

• AOD 9604 is commonly used by bodybuilders and fitness enthusiasts as a fat-loss aid during cutting phases. It is typically injected subcutaneously near adipose tissue deposits (e.g., abdomen or thighs) at doses of 300–1000 mcg per day, sometimes split into two doses.
• It is often stacked with other peptides (such as GHRP-2, GHRP-6, or IPA) or anabolic steroids, though such combinations are neither clinically validated nor safe.
• Proponents claim it preserves lean mass while reducing fat, but available human data do not demonstrate superiority over calorie restriction or exercise.

WADA and sport status

• AOD 9604 is prohibited at all times (in and out of competition) under the World Anti-Doping Agency (WADA) Prohibited List, specifically under S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics.
• It is specifically listed as a prohibited substance because it is a growth hormone fragment. Athletes testing positive face sanctions.